These drugs are rarely used as first-line treatments for HIV. Combination drugs combine multiple medications into one drug form. This type of regimen is typically used in people who have never ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

A new study led by Western researchers is the first to identify a factor that could influence how fast the pocket where human ...

Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency virus (HIV), a discovery that brings medical experts one step closer to a cure ...

A recent survey conducted by the HIV Medicine Association identified barriers to implementation of long-acting injectables for HIV prevention which included the need for prior authorization and ...

Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.